Gilead stock at 52-week high after FDA Yescarta label change, with earnings next
Gilead Sciences Inc notched a new 52-week high on Friday. The move came after the U.S. Food and Drug Administration signed off on a label update for Yescarta, the cancer cell therapy from its Kite unit, keeping attention on the stock as the week kicks off. Shares climbed 2.1% to $152.50.